Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
ABSTRACT: Introduction: After the development of acquired resistance to osimertinib, the standard-of-care treatment for advanced EGFR-mutated NSCLC is chemotherapy. Whether afatinib, a pan-ErbB family tyrosine kinase inhibitor, is active after progression on osimertinib is unknown. Methods: We cond...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Elsevier
2022-01-01
|
| Collection: | Cancer Treatment and Research Communications |
| Sujets: | |
| Accès en ligne: | http://www.sciencedirect.com/science/article/pii/S2468294221001933 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|